Arbutus Biopharma Corporation
NASDAQArbutus Biopharma heads into its August 19 earnings report with short sellers adding positions, the stock up on the week, and the lending market comfortably loose — a setup where the bearish thesis is growing in size but not yet in conviction. Short interest is the clearest signal worth watching. It has climbed to 10.6% of the free float, up roughly 6% in a single week and 9% over…
Snapshot as of 12 Aug 2026
Arbutus Biopharma heads into its August 19 earnings report with short sellers adding positions, the stock up on the week, and the lending market comfortably loose — a setup where the bearish thesis is growing in size…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ABUS — free to start on ORTEX.
Sign up for free →Open ABUS on ORTEX